These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30295837)

  • 1. Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.
    So W; Shurko J; Galega R; Quilitz R; Greene JN; Lee GC
    J Antimicrob Chemother; 2019 Jan; 74(1):269-271. PubMed ID: 30295837
    [No Abstract]   [Full Text] [Related]  

  • 2. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
    Plant AJ; Dunn A; Porter RJ
    Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
    [No Abstract]   [Full Text] [Related]  

  • 4. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
    Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
    Katzenstein TL; Faurholt-Jepsen D; Qvist T; Jensen PØ; Pressler T; Johansen HK; Kolpen M
    APMIS; 2023 Aug; 131(8):419-425. PubMed ID: 37294911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
    Poirel L; Ortiz De La Rosa JM; Kieffer N; Dubois V; Jayol A; Nordmann P
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
    Monogue ML; Nicolau DP
    J Antimicrob Chemother; 2018 Apr; 73(4):942-952. PubMed ID: 29272436
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Agyeman AA; López-Causapé C; Rogers KE; Lucas DD; Cortés-Lara S; Gomis-Font MA; Fraile-Ribot P; Figuerola J; Lang Y; Franklyn ERT; Lee WL; Zhou J; Zhang Y; Bulitta JB; Boyce JD; Nation RL; Oliver A; Landersdorfer CB
    Int J Antimicrob Agents; 2023 Sep; 62(3):106887. PubMed ID: 37315906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 13. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016 and 2019 in China.
    Yu W; Zhang H; Zhu Y; Jia P; Xu Y; Yang Q
    Int J Antimicrob Agents; 2023 Apr; 61(4):106741. PubMed ID: 36736928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
    Ortiz de la Rosa JM; Nordmann P; Poirel L
    J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.
    Skoglund E; Ledesma KR; Lasco TM; Tam VH
    J Glob Antimicrob Resist; 2017 Dec; 11():154-155. PubMed ID: 29101084
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study.
    García-Fernández S; García-Castillo M; Bou G; Calvo J; Cercenado E; Delgado M; Pitart C; Mulet X; Tormo N; Mendoza DL; Díaz-Regañón J; Cantón R;
    Int J Antimicrob Agents; 2019 May; 53(5):682-688. PubMed ID: 30769199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T; Zhanel GG; Schweizer F
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated Genome-Wide Analysis of an Isogenic Pair of
    Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.